Abbott, Gilead reveal topline results for oral hep C drugs

Abbott Laboratories ($ABT) shed more light on a promising mid-stage study of its interferon-free treatment for hepatitis C, showing the company is among the leaders in the crowded race to advance new all-oral therapies against the liver-damaging virus. After impressing analysts with topline results last month, Abbott revealed today that its triple-combo of antiviral drugs offered slightly better efficacy when given with ribavirin than without in its Phase IIb "Aviator" study. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.